Bélingard to leave Ipsen, de Garidel named CEO

Jean-Luc Bélingard, chairman and CEO of Ipsen, is leaving the company. Marc de Garidel has been named chairman and CEO to strengthen its U.S. and emerging markets operations. Ipsen release

> Caraco Pharmaceutical Laboratories has announced today that G. P. Singh Sachdeva will assume the position of CEO following the resignation of Jitendra Doshi as interim CEO and as a director--effective Nov. 1--due to personal and health-related reasons. Caraco release

> Shire has named Philip Vickers has been appointed senior VP of R&D for its human genetic therapies business. Shire release

> Iris International has appointed Amin Khalifa as corporate VP of finance effective immediately. He also will become the company's CFO to be effective on the day immediately following the filing of the Form 10-Q for the third quarter of 2010. Iris release

> Spectrum Pharmaceuticals has tapped Brett Scott as senior VP and acting CFO. Spectrum release

> Intrexon, a privately held synthetic biology company, has tapped William Fogler as senior director of portfolio analysis and planning for its Human Therapeutics Division.  Intrexon release

> Ricerca Biosciences, a preclinical contract research organization providing services to the biopharmaceutical industry, has announced the addition of Eric Lubert as a scientist in its drug safety division. Ricerca release

> Advaxis has appointed Robert Petit as the newly created position of VP of Clinical Operations and Medical Affairs, effective October 11, 2010. Dr. Petit will report to Dr. John Rothman, EVP of Science and Operations. Advaxis release

> Tetraphase Pharmaceuticals has named Garen Bohlin to its board of directors. Tetraphase release

> Acurian has hired Kim Basciani as director of eRecruitment to further the company's ability to recruit clinical trial participants via online strategies. Acurian release

> Ligand Pharmaceuticals has selected Sunil Patel to the company's board of directors. Ligand release

> NovaBay Pharmaceuticals has appointed Gail Maderis to its board of directors. Maderis will replace Harry Hixson, Jr. NovaBay release

> Biocept has named of Bruce Gerhardt as director. Biocept release

> G. Steven Burrill, founder and CEO, Burrill & Company, and James Geraghty, senior VP, Genzyme, have joined the organization's board of directors of BIO Ventures for Global Health. BVGH release

> Cempra Pharmaceuticals has announced that Richard Kent has been appointed to the company's board of directors. Kent will replace Garheng Kong as Intersouth's representative on the board. Cempra release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.